Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
阅读量：
125
摘要：
Despite the established efficacy of statins, many patients do not achieve recommended LDL cholesterol (LDL-C) goals. Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and increased potential for intolerance and adverse effects with combinations of available agents.In a double-blind study, 628 patients with baseline LDL-C 145 to 250 mg/dL and triglycerides < or =350 mg/dL were randomly assigned to receive 1 of the following for 12 weeks: ezetimibe (10 mg/d); atorvastatin (10, 20, 40, or 80 mg/d); ezetimibe (10 mg) plus atorvastatin (10, 20, 40, or 80 mg/d); or placebo. The primary efficacy end point was percentage reduction in LDL-C for pooled ezetimibe plus atorvastatin versus pooled atorvastatin treatment groups. Ezetimibe plus atorvastatin significantly improved LDL-C, HDL cholesterol (HDL-C), triglycerides, total cholesterol:HDL-C, and high-sensitivity C-reactive protein (hs-CRP) compared with atorvastatin alone (P<0.01). Coadministration of ezetimibe provided a significant additional 12% LDL-C reduction, 3% HDL-C increase, 8% triglyceride reduction, and 10% hs-CRP reduction versus atorvastatin alone. Ezetimibe plus atorvastatin provided LDL-C reductions of 50% to 60%, triglyceride reductions of 30% to 40%, and HDL-C increases of 5% to 9%, depending on atorvastatin dose. LDL-C reductions with ezetimibe plus 10 mg atorvastatin (50%) and 80 mg atorvastatin alone (51%) were similar.Ezetimibe plus atorvastatin was well tolerated, with a safety profile similar to atorvastatin alone and to placebo. When coadministered with atorvastatin, ezetimibe provided significant incremental reductions in LDL-C and triglycerides and increases in HDL-C. Coadministration of ezetimibe and atorvastatin offers a well-tolerated and highly efficacious new treatment option for patients with hypercholesterolemia.
展开
关键词：
Humans Musculoskeletal Diseases Azetidines Pyrroles Heptanoic Acids Triglycerides Treatment Outcome Prospective Studies Double-Blind Method Drug Therapy, Combination
DOI：
10.1161/01.CIR.0000068312.21969.C8
被引量：
年份：
2003
Taylor & Francis
Elsevier
(全网免费下载)
BMJ
万方医学
Semantic Scholar
(全网免费下载)
查看更多
dx.doi.org
NCBI
Europe PMC
Oxford Univ Press
ResearchGate
(全网免费下载)
EureKaMag.com
(全网免费下载)
ProQuest
ResearchGate
Citeseer
EBSCO
Citeseer
(全网免费下载)
jlr.org
core.ac.uk
(全网免费下载)
intl-circ.ahajournals.org
(全网免费下载)
circ.ahajournals.org
(全网免费下载)
365heart.com
(全网免费下载)
SAGE
onlinejacc.org
(全网免费下载)
mayoclinicproceedings.org
nejm.org
bvsalud.org
ajconline.org
eric.vcu.edu
(全网免费下载)
mendeley.com
lipidsonline.org
365heart.com
(全网免费下载)
mysciencework.com
pubfacts.com
internationaljournalofcardiology.com
jrnjournal.org
cjasn.asnjournals.org
dmsjournal.com
molpharm.aspetjournals.org
ajcn.nutrition.org
clinchem.org
cghjournal.org
cebp.aacrjournals.org
circ.ahajournals.org
www.socolar.com
Elsevier
(全网免费下载)
Semantic Scholar
(全网免费下载)
ResearchGate
(全网免费下载)
EureKaMag.com
(全网免费下载)
Citeseer
(全网免费下载)
onlinejacc.org
(全网免费下载)
circ.ahajournals.org
(全网免费下载)
365heart.com
(全网免费下载)
365heart.com
(全网免费下载)
eric.vcu.edu
(全网免费下载)
intl-circ.ahajournals.org
(全网免费下载)
core.ac.uk
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
